Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance OSI-906 plus Erlotinib vs Erlotinib plus Placebo in Advanced NSCLC
2010-020916-12Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing OSI-906 plus erlotinib with Erlotinib plus placebo (2 arms). Primary endpoint: progression-free survival. Started Oct 2010; status: completed.
02
Drugs
linsitiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-020916-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020916-12.